Loading your page…
Infection and drug resistance
By Pourmahdi-Torghabeh N, Izadi N, Boroumand Alipour M and 2 others.
Rising antimicrobial resistance in Salmonella and Shigella narrows therapeutic options, especially resistance to first-line agents like trimethoprim‑sulfamethoxazole and azithromycin.
Ward brings these articles into the same app as your cards and questions. One free account for Ward, Suture, Osler and Prognia.
We retrospectively analyzed 156 archived clinical isolates (Shigella n=108; Salmonella n=48) originally recovered from stool specimens collected between January 2017 and December 2020. Isolates were re-evaluated in a blinded manner using phenotypic susceptibility testing and PCR detection of dfrA1, sul1, ermB, mphA, and class 1 integron (IntI1).
S. sonnei was the predominant species (50.6%). Among Shigella and Salmonella isolates, resistance to trimethoprim-sulfamethoxazole and azithromycin was observed in 97.2% and 67.6% versus 16.7% and 20.8%, respectively. dfrA1 was detected in 97.2% of Shigella and 10.4% of Salmonella, while sul1 was detected in 58.3% and 14.8%, respectively. mphA was detected in 58.3% of Shigella but was absent in Salmonella, whereas ermB was detected in 0.04% and 58.3%, respectively. The PPV and NPV of ermB for phenotypic azithromycin resistance were 33.3% and 100%, respectively (κ=0.25, P<0.008). 20 Salmonella and two Shigella isolates harboring resistance-associated determinants were susceptible to azithromycin, while five Salmonella isolates with related genotypes remained susceptible to trimethoprim-sulfamethoxazole. MDR was observed in 55.6% of Shigella and 4.2% of Salmonella and was associated with IntI1 (χ2=31.99, P<0.001; Cramer's V=0.45).
Shigella and Salmonella showed distinct resistance and resistance-gene profiles. The low PPV and 100% NPV of ermB, together with genotype-phenotype discordance, indicate that molecular testing cannot replace phenotypic susceptibility testing for azithromycin resistance, although ermB may have potential rule-out value pending external validation. The association between IntI1 and MDR supports further investigation of class 1 integrons in multidrug resistance.
Published in Infection and drug resistance. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
